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Abstract
Aim: To evaluate the cardiovascular outcomes of glucagon-like peptide-1 receptor
agonists (GLP1-R A) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD).
Materials and Methods: We searched PubMed, Ovid MEDLINE, CINAHL, and Web
of Science databases for randomized controlled trials reporting event rates for a composite cardiovascular outcome of cardiovascular death, myocardial infarction, and
stroke in patients with T2DM and CKD receiving GLP1-R A or placebo. Studies were
restricted to those reporting specific event rates for patients with CKD separately
from the overall population. We conducted a meta-analysis using a random-effects
model. This meta-analysis was registered on PROSPERO (CRD42022320157).
Results: A total of four studies comprising 7130 patients was included in our analysis.
Four different GLP1-R A were assessed in a population with CKD defined as estimated
glomerular filtration rate (eGFR) <60 ml/min/1.73 m2. Treatment with GLP1-R A was
not associated with a significant reduction in the composite cardiovascular end point
of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (odds
ratio (OR) 0.80; 95% confidence interval (CI), 0.59–1.07; p = 0.13) among patients
with T2DM and CKD. Individual components of the composite cardiovascular end
point were assessed in two trials and did not show evidence of an effect of GLP1-R A
in reducing cardiovascular end points.
Conclusions: Pooled analysis of clinical trials reporting separate cardiovascular events
rates in patients with T2DM and CKD did not find GLP1-R A to be associated with a
reduction in composite cardiovascular event rates. Select GLP1-R A may offer cardiovascular event reduction in patients with T2DM and CKD, but this does not appear to
be a class effect. Use of GLP1-R A with demonstrated cardiovascular benefits should
be preferred in patients with CKD and T2DM to further reduce cardiovascular risk.
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I NTRO D U C TI O N

CINAHL, and Web of Science. Cited references were examined
and journals dedicated to diabetes research were also reviewed.

Cardiovascular disease (CVD) is the leading cause of death and

The initial search was performed in February 2022, with follow-up

comorbidity among patients with chronic kidney disease (CKD).1

searches performed on July 13, 2022. Search results were limited

Patients with type 2 diabetes mellitus (T2DM) and CKD have an

to the English language, human studies, and adult populations. No

even higher risk of developing CVD compared to the general popu-

date restrictions were included as part of the search. Search terms

lation. 2,3 Patients with CKD are more likely to die of CVD than reach

included a combination of index terms and keywords for ‘composite

end-stage renal disease (ESRD).4 Appropriately managing blood glu-

renal events’, ‘cardiovascular events’, ‘chronic kidney disease’, ‘type 2

cose, treating cardiovascular risk factors, and preserving renal func-

diabetes mellitus’, and ‘glucagon-like peptide-1 (GLP-1) analog’. This

tion is key to lowering cardiovascular risk in these patients.

5

meta-analysis was registered on PROSPERO (CRD42022320157).

Certain medications used to treat T2DM, such as sodium-glucose
cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP1-R A), have shown to be cardioprotective and/

2.2 | Study selection

6

or renoprotective in addition to lowering glucose. Proposed mechanisms of cardiovascular risk reduction seen with GLP1-R A can be

Two authors (M.K. and H.R.) independently reviewed all retrieved

attributed to non-glycemic benefits, such as weight and blood pres-

articles for inclusion using the following criteria: (i) randomized con-

sure reduction.7 In addition to that, their anti-inflammatory effects

trolled trial (RCT); (ii) evaluated a GLP1-R A (treatment group) against

and ability to reduce oxidative stress are other plausible mecha-

either a placebo or other active medication (comparator group); (iii)

nisms for reduction of kidney damage and thus, cardiovascular risk.1

study duration of 12 weeks or more; and (iv) reported cardiovascular

Current recommendations from the American Diabetes Association

event rates in treatment group and comparator group for patients

(ADA) and Kidney Disease Improving Global Outcomes (KDIGO)

with CKD. Reduced eGFR below 60 ml/min/1.73 m2 was used to de-

Diabetes Work Group recommend SGLT2 inhibitors with evidence

fine CKD in all articles. Articles were initially screened by review-

of reducing CKD progression for patients with CKD and elevated

ing abstracts; full-text articles were reviewed for studies meeting all

albuminuria.5,8 However, in patients with CKD without albumin-

inclusion criteria or when all inclusion criteria could not be assessed

uria or if an SGLT2 inhibitor cannot be used due to significant renal

by reviewing the abstract. Supplementary texts were evaluated for

dysfunction (estimated glomerular filtration rate (eGFR) < 25 ml/

subgroup analyses when reported in the full text. Disagreements

min/1.73 m2) or an intolerance, a GLP1-R A with demonstrated renal

about study inclusion were resolved by a third author (J.L.). The se-

benefit is recommended.5,8 A previous meta-analysis reported that

lection process and results are outlined in Figure 1.

GLP1-R A were associated with a 12% reduction in major adverse
cardiovascular events (MACE) relative to placebo among patients
with T2DM.9 More recently, a meta-analysis used pooled data from

2.3 | Data extraction and quality assessment

eight GLP1-R A cardiovascular outcome trials (CVOT) with 60,080
patients with T2DM.10 They reported a similar 14% reduction in

Data from included studies was abstracted by one author (J.C.) and

composite cardiovascular events with GLP1-R A use compared to

included study author and year, GLP1-R A and comparator, defini-

placebo. However, an assessment of the cardiovascular benefits

tion of CKD as defined in the study, cardiovascular end points evalu-

of GLP1-R A in patients with T2DM and CKD is more uncertain as

ated, number of patients with CKD in each group, and cardiovascular

most of the CVOT predominantly included patients without CKD.

event rates for each group. Composite cardiovascular events, which

Considering that a diagnosis of CKD in addition to T2DM amplifies

included cardiovascular death, nonfatal myocardial infarction (MI)

CVD risk, our systematic review and meta-analysis aims to assess

and stroke, as well as event rates for each individual event of the

the cardiovascular benefits of GLP1-R A in patients with concomi-

composite end point were collected. Study quality of included trials

tant T2DM and CKD.

was evaluated independently by two authors (H.R. and J.L.) using
the Cochrane risk-of-bias tool for randomized controlled trials ver-
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M ATE R I A L S A N D M E TH O DS

sion 2 (RoB2)12 (Appendix S2).

2.1 | Data sources and search criteria

2.4 | Statistical analysis

The reporting of this systematic review was guided by the stand-

For each study included in the analysis, the number of patients with

ards of the Preferred Reporting Items for Systematic Review and

positive and negative cardiovascular end points was determined

11

Meta-Analysis (PRISMA) Statement.

A systematic search strategy

for both GLP1-R A treatment and placebo. Binary outcomes were

was developed according to PRISMA guidelines (Appendix S1). The

reported as odds ratios. Fixed (common) and random-effects cal-

search strategy and search were conducted by a health sciences

culations were done using the Mantel–Haenszel method for pool-

librarian on the following databases: PubMed, Ovid MEDLINE,

ing the studies. Between-study variance (tau2) was computed using
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F I G U R E 1 Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow diagram of identified studies. CKD,
chronic kidney disease; CINAHL, Cumulative Index to Nursing and Allied Health Literature; GLP1-R A, glucagon-like peptide-1 receptor
agonists; OVID, Offshore Vessel Inspection Database; RCT, randomized controlled trial

restricted maximum likelihood and the Q-profile method was used
2

13

to compute the confidence interval of tau and tau.

stroke. Two studies14,15 also reported event rates for each of the

Heterogeneity

individual outcomes. Each trial was considered to have an overall

was assessed using a Cochrane Q and quantified using the I2 statis-

low risk of bias based on the assessment tool used (Appendix S2).12

tic, which shows the variance attributable to heterogeneity as a per-

Information related to included studies and the original CVOT is

centage, with p-values below 0.05 considered to indicate significant

shown in Table 1.

heterogeneity. Statistical analysis was done using The R Project for
Scientific Computing version 4.1.1 on Rstudio with “meta” package
(R Core Team 2021, Vienna, Austria).

3
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3.1 | Composite cardiovascular outcome
In the pooled analysis using a random-effects model, treatment with

R E S U LT S

GLP1-R A was not associated with a significant reduction in the composite cardiovascular end point in patients with CKD (odds ratio (OR)

A total of 81 full-text articles were identified with our search cri-

0.80; 95% confidence interval (CI), 0.59–1.07; p = 0.13) (Figure 2).

teria. Among those, four studies comprising 7130 patients met our

Three GLP1-R A (liraglutide, oral and subcutaneous semaglutide)

study inclusion criteria and were included in the analysis.14–17 The

were associated with a lower risk of the composite end point15–17 but

patients with CKD that were included in our analysis come from sub-

only one of these agents, liraglutide,15 demonstrated a statistically

16–19

Inclusion criteria for each CVOT

significant result for the composite cardiovascular outcome. The

varied but the proportion of patients with established CVD ranged

group analyses of four CVOT.

fourth GLP1-R A, exenatide, was associated with a non-significant

from 73% to 85%. Each study included in our analysis evaluated a

increase in OR for the composite outcome.14

different GLP1-R A, including once-daily liraglutide, once-weekly
exenatide, once-weekly subcutaneous semaglutide, and once-daily
oral semaglutide.14–17 All studies evaluated patients with CKD defined as eGFR <60 ml/min/1.73 m2, although two studies14,16 ex-

cluded patients with an eGFR <30 ml/min/1.73 m2. The percent of

3.2 | Individual cardiovascular outcomes
Only two studies14,15 reported event rates for individual compo-

patients in the original four CVOT who had CKD ranged from 22.9%

nents of the composite end point for the CKD population (Figure 3).

to 28.5%.16–19 The composite cardiovascular end point assessed in

Similar to the OR for the composite cardiovascular outcome, there

each study included cardiovascular death, nonfatal MI, and nonfatal

was no evidence of benefit in lowering risk of cardiovascular death
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Age ≥ 50 years and ≥1 of the
following:
• Prior MI, stroke, TIA
• History of symptomatic CHD
• Asymptomatic cardiac
ischemia
• NYHA Class II-III
• CKD eGFR <60 ml/
min/1.73 m2
• T2DM and age ≥ 50 years with
established CVD
• CKD or age ≥ 60 years with CV
risk factors
• T2DM age ≥ 50 years with
established CVD, chronic HF,
or CKD stage 3 or higher
• T2DM age ≥ 60 years with CVD
or ≥1 CV risk factor

LEADER
(n = 9340)

PIONEER-6
(n = 3183)

SUSTAIN-6
(n = 3297)

Mann et al. (2018)15

Husain et al.
(2019)16

Marso et al.
(2016)17

939 (28.5%)

856 (26.9%)

2158 (23.1%)

3177 (22.9%)

Number of patients
w/CKD (%)

eGFR<60 ml/
min/1.73 m2

eGFR 30–59 ml/
min/1.73m2

eGFR <60 ml/
min/1.73 m2

eGFR 30–59 ml/
min/1.73 m2

How CKD defined

Semaglutide 0.5 or 1 mg
weekly vs Placebo

Semaglutide 14 mg daily
vs Placebo

Liraglutide 1.8 mg daily vs
placebo

Exenatide 2 mg weekly vs
placebo

GLP1-R A vs comparator

Median 2.1 years

Median
15.9 months

Median 3.8 years

Median 3.2 years

Study duration

3-point composite
MACE

3-point composite
MACE

3-point composite
MACE

3-point composite
MACE

CV composite
outcome
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Abbreviations: 3-point composite MACE = major adverse cardiovascular events; CHD = coronary heart disease; CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease;
eGFR = estimated glomerular filtration rate; GLP1-R A = glucagon-like peptide-1 receptor agonist; HF = heart failure; MI = myocardial infarction; NYHA = New York Heart Association; TIA = transient
ischemic attack; T2DM = type 2 diabetes mellitus.

T2DM on ≤3 oral agents or
insulin therapy alone or in
combo with ≤2 oral agents

EXSCEL
(n = 14,752)

Bethel et al.
(2020)14

Inclusion criteria for CVOT

Original CVOT (n)

CKD subgroup
study

TA B L E 1 Summary of baseline demographic data of included studies

4

5

F I G U R E 2 Composite cardiovascular outcomes. CI, confidence interval; GLP1, glucagon-like peptide-1; OR, odds ratio

F I G U R E 3 Cardiovascular death, myocardial infarction, and stroke individual outcomes. CI, confidence interval; GLP1, glucagon-like
peptide-1; OR = odds ratio
(OR 0.83; 95% CI, 0.5–1.36; p = 0.46), nonfatal MI (OR 0.85; 95% CI,

specific event rates from CVOT and did not observe a benefit of

0.63–1.15; p = 0.30), and nonfatal stroke (OR 0.78; 95% CI, 0.33–

GLP1-R A in reducing composite cardiovascular outcomes. In pre-

1.86; p = 0.58) with GLP1-R A compared to placebo.

vious meta-analyses, which utilized pooled hazard ratios,9,10 subgroup analyses by CKD status showed GLP1-R A were associated

4

|

DISCUSSION

with a lower risk of composite cardiovascular events in patients
with and without CKD, defined as eGFR below or greater than
60 ml/min/1.73 m2, respectively, at baseline. In the meta-analysis

Our meta-analysis is the first to assess the effects of GLP1-R A on

by Kristensen et al.,9 GLP1-R A was associated with a reduced haz-

cardiovascular events in patients with T2DM and CKD by evaluating

ard ratio (HR) for the 3-point MACE outcome in patients with CKD
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(HR 0.88; 95% CI, 0.76–1.03), which was similar to the study group

other GLP1-R A evaluated in our meta-analysis were associated

without CKD (HR 0.85; 95% CI, 0.76–0.96) p = 0.72. Likewise, in

with reduced cardiovascular event rates among patients with CKD,

the more recent meta-analysis by Sattar et al.,10 the 3-point MACE

with the largest absolute reductions reported with liraglutide and

outcome was lower in patients with CKD (HR 0.88; 95% CI, 0.77–

once-weekly semaglutide.15,17 Similarly, the meta-analysis by

1.01) and without CKD (HR 0.83; 95% CI, 0.74–0.93) treated with

Kristensen et al.9 reported possible heterogeneity between GLP-1

GLP1-R A. Interestingly, both analyses reported identical compos-

homology, although comparison did not reach statistical significance

ite cardiovascular event rates for eGFR subgroups. In patients with

(p-interaction = 0.06).

baseline eGFR of 60 ml/min/1.73 m2 or higher, composite cardiovas-

The neutral effects of exenatide may be explained by the fact

cular event rates for GLP1-R A versus placebo were 9% versus 10%,

that it is dissimilar to other GLP1-R A with regard to renal effects.

while composite event rates in patients with baseline eGFR below

Once-weekly exenatide is not recommended in patients with eGFR

60 ml/min/1.73 m2 were 14% versus 16%, respectively. Based on the

<30 ml/min/1.73 m2 due to increased and unpredictable drug ex-

reported event rates, patients with CKD have higher cardiovascular

posure. 20 Exenatide is an exendin-4 analog, which is metabolized

event rates and treatment with GLP1-R A is associated with a greater

and eliminated by the kidneys, and could accumulate in patients

absolute risk reduction (2%) compared to non-CKD patients (1%).

with CKD. Alternatively, human GLP1-R A analogs (such as liraglu-

However, our analysis evaluating specific reported event rates in pa-

tide, semaglutide, and dulaglutide) are not eliminated by the kidneys

tients with CKD did not find GLP1-R A to be associated with reduced

and may be used in patients with CKD, including patients receiving

composite cardiovascular event rates.

hemodialysis, without dose adjustment. 21–24 Additionally, positive

The lack of evidence of supporting reduced cardiovascular

composite renal outcomes have been demonstrated with several

events found in our meta-analysis may be explained by a low per-

GLP1-R A (liraglutide, dulaglutide, and semaglutide)10 whereas ex-

centage of patients with CKD included in CVOT evaluating patients

enatide had no significant effect on the composite renal outcome

with T2DM treated with GLP1-R A, as well as a potential confound-

among the population studied in the EXSCEL trial.14 An ongoing

ing effect of exenatide treatment. Our data were generated from

phase 3 clinical trial, the FLOW trial (NCT03819153), will assess

CVOT reporting specific event rates in the study population with

the effects of once-weekly semaglutide compared to placebo on

CKD, but none of these trials were powered to assess treatment

the composite renal and cardiovascular death end point among

differences in CKD subgroups. In previous analyses by Kristensen

patients with T2DM and CKD receiving maximally tolerated renin-

and Sattar, the proportion of patients with CKD was 19% and 20%,

angiotensin-aldosterone system inhibiting medications.

respectively.9,10 Our analysis included four trials,” which reported

The recently updated 2022 ADA Standards of Medical Care in

cardiovascular event rates for the CKD subgroup separately from

Diabetes guidelines now includes a stand-alone chapter on man-

the overall population. The number of patients with CKD in these

aging CKD and provides specific recommendations for preferred

four trials ranged from 23% to 28.5% of the entire population stud-

antihyperglycemic agents in patients with T2DM. 25 An SGLT2

ied in the original CVOT. Therefore, we believe the proportion of

inhibitor is recommended for patients with CKD and elevated

patients with CKD assessed in our analysis to be of adequate size for

albuminuria, but either a GLP1-R A or SGLT2 inhibitor with demon-

subgroup analysis.

strated cardiovascular risk reduction is recommended for patients

Perhaps the most compelling explanation for the lack of statisti-

with CKD without albuminuria to lower cardiovascular risk. 8 In

cal significance in our analysis may be due to the neutral cardiovas-

the event that patients are unable to take an SGLT2 inhibitor due

cular effects of exenatide. The exenatide CVOT (EXSCEL) evaluated

to adverse effects or significant renal dysfunction (eGFR <25 ml/

the effect of once-weekly exenatide on major cardiovascular events

min/1.73 m2), a GLP1-R A may be used in its place given the ele-

among patients with T2DM and increased cardiovascular risk.19

vated cardiovascular risk associated with T2DM and CKD. Adverse

This study included 14,752 patients, which is the largest sample

effects of SGLT2 inhibitors are well characterized and mainly in-

size among GLP1-R A CVOT included in our analysis, and excluded

clude genitourinary infections. 26 The risk of euglycemic diabetic

2

patients with an eGFR <30 ml/min/1.73 m . Over a study period of

ketoacidosis may also be of concern, especially in patients with

3.2 years, exenatide did not significantly reduce the risk of MACE

advanced CKD, as SGLT2 inhibitors appear to promote ketogen-

compared to placebo (HR 0.91; 95% CI, 0.83–1.00). In our analysis,

esis and reduce renal elimination of ketones. 27 In the event that

the EXSCEL trial included the lowest percentage of patients with

there is a concern for these adverse effects, a GLP1-R A may be

a reduced eGFR (22.9%), but accounted for the largest weighted

the preferred option.

effect of the pooled analysis (32.9%) due the large sample size of

Our study has a few limitations. First, only four studies met our

the overall trial. Subgroup analysis of the EXSCEL trial found no

inclusion criteria in providing individual event rates for the CKD

treatment effect by CKD status, yet composite cardiovascular event

subgroup, which may limit the generalizability of our findings to

rates appeared to be higher in patients across all CKD subgroups

the four GLP1-R A studied in those trials. Additionally, the propor-

who received exenatide versus placebo. For example, the compos-

tion of patients with CKD included in the original CVOT was low,

ite cardiovascular event rate occurred at a higher rate in patients

and none of the trials were powered to assess cardiovascular end

with eGFR below 60 ml/min/1.73 m2 treated with exenatide com-

points between patients with and without CKD. Furthermore, our I2

pared to placebo (18.1% exenatide vs 17.5% placebo). Conversely,

statistic values appear high (79% for the composite cardiovascular
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end point), suggesting a high proportion of total variability due to
between-study heterogeneity. This may be due to differences in the
GLP1-R A studied, the proportion of patients with previous CVD,
and potential differences in use of other medications associated
with improved cardiovascular benefit. For example, the proportion
of patients with established CVD was 73% in the EXSCEL trial and
85% in the PIONEER-6 study.14,16 Additionally, SGLT2-inhibitor use
was reported in 10% of patients from PIONEER-6 compared to 1%
in EXSCEL. Lastly, the patients with CKD who were included in our
study may also have other risk factors contributing to high CVD risk.
We did not account for additional CVD risk factors, other than CKD,
which could have influenced cardiovascular event rates and the effects of the GLP1-R A.

5
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CO N C LU S I O N

The presence of CKD concomitantly with T2DM increases CVD risk.
Select GLP1-R A have shown reduced cardiovascular event rates
in patients with T2DM and elevated cardiovascular risk (including
CKD); however, our meta-analysis found that GLP1-R A was not associated with reduced risk of the composite cardiovascular end point
in a subgroup population with T2DM and CKD compared to placebo.
The limited number of included trials or heterogeneity of evaluated
GLP1-R A may explain the lack of cardiovascular effect associated
with GLP1-R A in the CKD patient subgroup. Based on available clinical trials and subgroup analysis, use of GLP1-R A with demonstrated
renal and cardiovascular benefits (such as liraglutide or once-weekly
semaglutide) should be preferred in patients with CKD and T2DM to
further reduce cardiovascular risk. Additional studies to evaluate the
cardiovascular effects of GLP1-R A in patients with T2DM and CKD
would be useful to determine if this class does reduce composite
cardiovascular event rates in this subgroup population.
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